20/20 Qualified Under Reg. A+

‌

August 28, 2018

Greetings!

We are pleased to report that following a 5 month intensive review by the U.S. Securities & Exchange Commission (SEC) and FINRA, 20/20's Regulation A Offering has now been qualified by the SEC. Fewer than 250 companies have been Reg A Qualified to date, of which no more than 10 have been in the biomedical fields.

Please consider making an investment in our Series B round and/or referring this communication to others in your network. Our Reg A qualification permits us to raise capital from investors at nearly all income levels, including those who are not accredited. Nearly one million dollars has already been invested in less than three full business days since our campaign publicly launched. Information about our company and this offering is available on SeedInvest.

There are several advantages of investing in a Reg. A+ offering (vs. a traditional private placement), including more transparency and liquidity. For more on this, please read "Three Big Advantages of Investing in a Reg A+ Qualified Company ".

If you are interested in learning more, you may do so here .

Sincerely,

20/20 Management Team

For more information click below to download

1st Quarter '18 Report
2nd Quarter '18 Report
August '18 Annual Meeting Slide Deck (Contact Chris Pedraza if you would like to receive the video recording of this presentation.)

Regulation A

20/20 GeneSystems is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. The Final Offering Circular that forms a part of the Offering Statement may be downloaded here: https://www.seedinvest.com/2020.genesystems

https://www.seedinvest.com/2020.genesystems

Investing in an initial public offering under Regulation A is subject to unique risks, tolerance for volatility, and potential loss of principal, that customers should be aware of prior to making an investment decision . For more information about Regulation A offerings, including the unique risks associated with these types of offerings, please click on the SEC's Reg. A Investor Bulletin .

Forward-Looking Statements

Some of the statements in this document including statements regarding a future offering of the Company's securities under Regulation A, the potential success of any such offering, and the Company's ability to successfully sell and commercialize its cancer diagnostic products, constitute forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends, and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "should", "will" and "would" or the negatives of these terms or other comparable terminology.

You should not place undue reliance on forward looking statements. The cautionary statements set forth in the Form 1-A with the SEC in March 2018, including in "Risk Factors" and elsewhere therein, identify important factors which you should consider in evaluating our forward-looking statements.

Although the forward-looking statements in this document are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements, or outcomes. No assurance can be made that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law.